Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) is featured in a BioMedWire editorial that examines the urgent need for new approaches to treating multiple sclerosis (MS), a progressive neurological disease affecting over 2.9 million people worldwide. The editorial, titled “The Quest to Repair What Multiple Sclerosis Takes Away,” highlights the limitations of current therapies, which can slow disease progression but cannot stop it completely.
The editorial discusses Quantum BioPharma’s development of Lucid-MS, a patented, first-in-class drug candidate designed to directly target the myelin sheath damaged by MS. The company said the potential therapy is preparing to advance into Phase 2 clinical trials as it pursues a novel approach to treating the disease. Myelin degradation is the underlying mechanism of MS, and Lucid-MS has shown in preclinical models the ability to prevent and reverse this degradation.
This development is significant because MS remains a debilitating condition with no cure. Current disease-modifying therapies primarily focus on reducing inflammation and slowing progression, but they do not repair existing damage. If successful, Lucid-MS could represent a paradigm shift by actively remyelinating neurons, potentially restoring function and improving quality of life for patients.
Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets for neurodegenerative, metabolic, and alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., Quantum is focused on Lucid-MS. The company also invented UNBUZZD, a product for alcohol misuse, and retains ownership in Unbuzzd Wellness Inc., along with royalty payments.
For more information on the editorial, visit https://ibn.fm/WikKX. The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM.
